| Members |
targetComponentId |
| Drug cream, 0,1% |
Cream |
| Drug cream, 0,25% |
Cream |
| Drug cream, 0,5% |
Cream |
| Drug cream, 1% |
Cream |
| Drug cream, 2,5% |
Cream |
| pharmacodépendance |
Substance dependence (disorder) |
| Drug dependence - unspecified whether during pregnancy or the puerperium |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence NOS |
Substance dependence (disorder) |
| Drug dependence NOS |
Substance dependence (disorder) |
| Drug dependence during childbirth, puerperium (& pregnancy) |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence during pregnancy, childbirth and the puerperium |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence during pregnancy, childbirth or the puerperium NOS |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence in childbirth |
Substance dependence in childbirth |
| Drug dependence in mother complicating pregnancy, childbirth AND/OR puerperium |
Substance dependence in mother complicating pregnancy, childbirth and/or puerperium (disorder) |
| Drug dependence in remission |
Substance dependence in remission |
| Drug dependence, continuous |
Substance dependence, continuous |
| Drug dependence, episodic |
Substance dependence, episodic (disorder) |
| Drug gel, 0,05% |
Gel |
| Drug gel, 0,1% |
Gel |
| Drug gel, 0,25% |
Gel |
| Drug groups and agents primarily acting on skin adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting autonomic nervous system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting cardiovascular system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting central nervous system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting gastrointestinal system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting musculoskeletal system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting respiratory system adverse reaction |
Adverse reaction to drug |
| Drug groups primarily affecting the autonomic nervous system |
Product containing autonomic agent (product) |
| Drug induced rash (& ingestion dermatitis) |
Dermatitis caused by substance taken via oral route (disorder) |
| Drug level in urine specimen above therapeutic range |
Urine substance level above reference range (finding) |
| Drug ointment, 0,025% |
Ointment |
| Drug ointment, 0,05% |
Ointment |
| Drug ointment, 0,1% |
Ointment |
| Drug ointment, 0,2% |
Ointment |
| Drug ointment, 0,25% |
Ointment |
| Drug ointment, 1% |
Ointment |
| Drug ointment, 2,5% |
Ointment |
| Drug reaction - CNS drug |
Adverse reaction to drug |
| Drug reaction - CNS drug |
Adverse reaction to drug |
| Drug reaction - CNS drug NOS |
Adverse reaction to drug |
| Drug reaction - CNS drug NOS |
Adverse reaction to drug |
| Drug specific allergen extract |
Pharmaceutical / biologic product (product) |
| sevrage d'une drogue |
Substance withdrawal |
| Drug withdrawal seizure |
Seizure co-occurrent and due to substance withdrawal |
| Drug withdrawal syndrome |
Substance withdrawal |
| Drug withdrawal syndrome |
Substance withdrawal |
| Drug, medicament or biological substance |
Drug or medicament (substance) |
| Drug, medicament, or biological substance in urine above reference range |
Urine substance level above reference range (finding) |
| impuissance médicamenteuse |
Erectile dysfunction caused by drug |
| diabète insipide néphrogénique médicamenteux |
Acquired nephrogenic diabetes insipidus |
| trouble causé par un médicament |
Disease |
| Drugs in urine abnormal [D] |
Substance in urine detected by screening method (finding) |
| médicaments utilisés pour traiter l'hyperuricémie |
Uricosuric agent |
| médicaments utilisés dans les troubles métaboliques |
Medicinal product categorised by therapeutic role |
| Drusen |
Hyaline body |
| Dry battery contents causing toxic effect |
Toxic effect of sulfuric acid |
| Duct ectasia |
Dilatation |
| Ductal carcinoma in situ - category |
Non-infiltrating intraductal carcinoma |
| Dukes-Filatow disease |
Rubeola scarlatinosa |
| Dundee cardiovascular risk score |
Dundee Coronary Risk Disk (assessment scale) |
| Duodenitis caused by ingestible alcohol |
Duodenitis caused by ethanol (disorder) |
| Duodenoscopy: [diagnostic NOS] or [NEC] |
Duodenoscopy |
| concept en double |
Duplicate component (foundation metadata concept) |
| rapport en double |
Duplicate report (record artifact) |
| maladie de Dupuytren traitée par section de l'aponévrose palmaire |
Dupuytren contracture corrected by division of palmar aponeurosis |
| Dupuytren's disease of finger(s), nodules with no contracture |
Dupuytren's disease of finger |
| Dupuytren's disease of palm, nodules with no contracture |
Dupuytren's disease of palm |
| Dyclonine hydrochloride 1% topical solution (product) |
Product containing precisely dyclonine hydrochloride 10 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
| Dynamite, device |
Dynamite stick (physical object) |
| Dyphylline + guaifenesin 100mg/100mg elixir |
Product containing precisely diprophylline 6.67 milligram/1 milliliter and guaifenesin 6.67 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Dyphylline 160mg/15ml elixir |
Diprophylline 10.7 mg/mL oral solution |
| Dyskinesia of esophagus |
Diffuse spasm of esophagus |
| Dyssegmental dysplasia with glaucoma syndrome |
Rolland-Debuqois syndrome |
| Dyssocial behavior of child or adolescent |
Dyssocial behavior of child or adolescent (finding) |
| Dysthyroid ophthalmopathy |
Exophthalmos due to thyroid eye disease (disorder) |
| rapport envoyé par courriel |
Email report (record artifact) |
| ECG equivocal |
ECG equivocal |
| ECG: left ventricular strain |
ECG: left ventricular strain |
| Ear flap |
Flap (substance) |
| Ear sign or symptom |
Ear and auditory finding (finding) |
| Ear/nose/throat symptom NOS |
Ear, nose and throat finding |
| Ear/nose/throat symptom NOS |
Ear, nose and throat finding |
| Ear/nose/throat symptoms NOS |
Ear, nose and throat finding |
| Ear/nose/throat symptoms NOS |
Ear, nose and throat finding |
| Early onset pauciarticular chronic arthritis |
Juvenile idiopathic arthritis, oligoarthritis (disorder) |
| Early operation NOC NOS |
Surgical procedure (procedure) |
| Early operation NOC OS |
Surgical procedure (procedure) |
| Early operations NOC |
Surgical procedure (procedure) |
| Ebola virus |
Genus Ebolavirus (organism) |
| Ebola virus Ivory Coast subtype |
Ivory Coast ebolavirus (organism) |
| Ebola virus Reston biotype |
Reston ebolavirus (organism) |
| Ebola virus Sudan biotype |
Sudan ebolavirus (organism) |
| Ebola virus Zaire biotype |
Zaire virus (organism) |
| Ebola virus disease |
Ebola virus disease |
| Eccrine papillary adenocarcinoma |
Digital papillary adenocarcinoma |
| Echinococcus granulosus infection of other site |
Echinococcus granulosus infection |
| Echinococcus multilocularis infection of other site |
Echinococcus multilocularis infection |
| Echinocyte |
Burr cell |
| Echothiophate iodide 0.03% eye drops |
Ecothiopate iodide 300 microgram/mL eye solution |
| Echothiophate iodide 0.06% eye drops |
Product containing precisely ecothiopate iodide 600 microgram/1 milliliter conventional release eye solution (clinical drug) |
| Echothiophate iodide 0.125% solution |
Ecothiopate (as ecothiopate iodide) 1.25 mg/mL eye solution |